Bionovo, Inc. is a development-stage enterprise engaged in the development of pharmaceuticals, derived from botanical sources, to treat cancer and women�s health. Its drug candidate, Menerba (formerly MF-101), represents a class of receptor sub-type selective estrogen receptor modulator (SERM), for the treatment of vasomotor symptoms of menopause, or hot flashes. The Company has designed Menerba to modulate estrogen receptor beta (ER). In preclinical studies, Menerba does not lead to tumor formation in either breast or uterine tissues. The Company is also developing Bezielle, an oral anticancer agent for advanced breast cancer. Bezielle is designed to take advantage of a metabolism of cancer cells, with a well-characterized mechanism of action, which leads to selective tumor cell Deoxyribonucleic Acid (DNA) damage and the death of cancer cells. The Company treated 48 women with metastatic breast cancer with Bezielle in two separate Phase I clinical trials.